Drug Binding Assays do not Reveal Specific Binding of Lacosamide to Collapsin Response Mediator Protein 2 (CRMP-2)

CNS Neuroscience and Therapeutics

Volumn 18, Issue 6, 2012, Pages 493-500

  Wolff, Christian ^a   Carrington, Bruce ^a   Varrin Doyer, Michel ^b   Vandendriessche, Anne ^a   Van der Perren, Christy ^a   Famelart, Michel ^a   Gillard, Michel ^a   Foerch, Patrik ^a   Rogemond, Véronique ^c,d,e   Honnorat, Jerôme ^c,d,e   Lawson, Alastair ^a   Miller, Karen ^a  

^a UCB PHARMA   (Belgium)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CNRS   (France)

^d HÔPITAL NEUROLOGIQUE   (France)

^e UNIVERSITÉ LYON 1   (France)

Author keywords

CRMP 2; Epilepsy; Lacosamide; Mechanism of action

Indexed keywords

COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; HARKOSERIDE; RADIOLIGAND;

ARTICLE; BACTERIUM; DRUG BINDING; HUMAN; HUMAN CELL; MALE; MAMMAL CELL; SURFACE PLASMON RESONANCE;

ACETAMIDES; ANIMALS; ANTICONVULSANTS; BRAIN; CELL LINE, TRANSFORMED; CELL MEMBRANE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICROINJECTIONS; NERVE TISSUE PROTEINS; OOCYTES; PROTEIN BINDING; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; SURFACE PLASMON RESONANCE; TRANSFECTION; TRITIUM; XENOPUS;

EID: 84861913387     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2012.00313.x     Document Type: Article

References (21)

1. 2008 VIMPAT® (lacosamide) Prescribing Information. UCB, Inc., Smyrna, GA, US ).
2. 2008 VIMPAT® Summary of Product Characteristics for Lacosamide. UCB Pharma, S.A., Belgium ).
3. Errington AC, Stohr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008;73:157-169.
4. Sheets PL, Heers C, Stoehr T, Cummins TR. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine. J Pharmacol Exp Ther 2008;326:89-99.
5. Beyreuther BK, Freitag J, Heers C, Krebsfanger N, Scharfenecker U, Stohr T. Lacosamide: A review of preclinical properties. CNS Drug Rev 2007;13:21-42.
6. Park KD, Morieux P, Salome C, et al. Lacosamide isothiocyanate-based agents: Novel agents to target and identify lacosamide receptors. J Med Chem 2009;52:6897-6911.
7. Wang Y, Brittain JM, Jarecki BW, et al. In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation. J Biol Chem 2010;285:25296-25307.
8. Charrier E, Reibel S, Rogemond V, Aguera M, Thomasset N, Honnorat J. Collapsin response mediator proteins (CRMPs): Involvement in nervous system development and adult neurodegenerative disorders. Mol Neurobiol 2003;28:51-64.
9. Wang Y, Brittain JM, Wilson SM, Khanna R. Emerging roles of collapsin response mediator proteins (CRMPs) as regulators of voltage-gated calcium channels and synaptic transmission. Commun Integr Biol 2010;3:172-175.
10. Schmidt EF, Strittmatter SM. The CRMP family of proteins and their role in Sema3A signaling. Adv Exp Med Biol 2007;600:1-11.
11. Hensley K, Venkova K, Christov A, Gunning W, Park J. Collapsin Response mediator Protein-2: An emerging pathologic feature and therapeutic target for neurodisease indications. Mol Neurobiol 2011;43:180-191.
12. Czech T, Yang J, Csaszar E, Kappler J, Baumgartner C, Lubec G. Reduction of hippocampal collapsin response mediated protein-2 in patients with mesial temporal lobe epilepsy. Neurochem Res 2004;29:2189-2196.
13. 3H]linopirdine binding to rat brain membranes is not relevant for M-channel interaction. Eur J Pharmacol 2005;518:10-17.
14. Takahashi T, Fournier A, Nakamura F, et al. Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors. Cell 1999;99:59-69.
15. Karlsson R, Stahlberg R. Surface plasmon resonance detection and multispot sensing for direct monitoring of interactions involving low-molecular-weight analytes and for determination of low affinities. Anal Biochem 1995;228:274-280.
16. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh S M, Matagne A, Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004;101:9861-9866.
17. Deo RC, Schmidt EF, Elhabazi A, Togashi H, Burley SK, Strittmatter SM. Structural bases for CRMP function in plexin-dependent semaphorin3A signaling. EMBO J 2004;23:9-22.
18. Stenmark P, Ogg D, Flodin S, et al. The structure of human collapsin response mediator protein 2, a regulator of axonal growth. J Neurochem 2007;101:906-917.
19. Kawano Y, Yoshimura T, Tsuboi D, et al. CRMP-2 is involved in kinesin-1-dependent transport of the Sra-1/WAVE1 complex and axon formation. Mol Cell Biol 2005;25:9920-9935.
20. Chi XX, Schmutzler BS, Brittain JM, Wang Y, Hingtgen CM, Nicol GD, Khanna R. Regulation of N-type voltage-gated calcium channels (Cav2.2) and transmitter release by collapsin response mediator protein-2 (CRMP-2) in sensory neurons. J Cell Sci 2009;122:4351-4362.
21. Sake JK, Hebert D, Isojarvi J, et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs 2010;24:1055-1068.